S
Shameem Mohammad
Researcher at Aligarh Muslim University
Publications - 2
Citations - 280
Shameem Mohammad is an academic researcher from Aligarh Muslim University. The author has contributed to research in topics: Vaccine efficacy & Adverse effect. The author has an hindex of 2, co-authored 2 publications receiving 30 citations.
Papers
More filters
Journal ArticleDOI
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.
Raches Ella,Siddarth Reddy,William C. Blackwelder,Varsha Potdar,Pragya D Yadav,Vamshi Sarangi,Vinay Kumar Aileni,Suman Kanungo,Sanjay K Rai,P. Prabhakar Reddy,Savita Verma,Chandramani Singh,Sagar Vivek Redkar,Satyajit Mohapatra,Anil Pandey,Pajanivel Ranganadin,Raghavendra Gumashta,Manish Multani,Shameem Mohammad,Parul Bhatt,Laxmi Kumari,Gajanan Sapkal,Nivedita Gupta,Priya Abraham,Samiran Panda,Sai Prasad,Balram Bhargava,Krishna Murthy Ella,Krishna Mohan Vadrevu +28 more
TL;DR: In this article, the authors reported the clinical efficacy against COVID-19 infection of BBV152, a whole virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG) in Indian adults.
Posted ContentDOI
Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomised, controlled phase 3 trial
Raches Ella Mbbs,Siddharth Reddy,William C. Blackwelder,Varsha Potdar,Pragya D Yadav,Vamshi Sarangi,Vinay Kumar Aileni,Suman Kanungo,Sanjay K Rai,P. Prabhakar Reddy,Savitha Verma,Chandramani Singh,Sagar Vivek Redkar,Satyajit Mohapatra,Anil Kumar Pandey,Pajanivel Ranganadin,Raghavendra Gumashta,Manish Multani,Shameem Mohammad,Parul Bhatt,Laxmi Kumari,Gajanan Sapkal,Nivedita Gupta,Priya Abraham,Samiran Panda,Sai Prasad,Balram Bhargava,Krishna Murthy Ella,Krishna Mohan Vadrevu +28 more
TL;DR: A double-blind, randomised, multicentre, phase 3 clinical trial in 25 Indian hospitals to evaluate the efficacy, safety, and immunological lot consistency of BBV152, a whole-virion inactivated SARS-CoV-2 vaccine formulated with a Toll-like receptor 7/8 agonist molecule adsorbed to alum as discussed by the authors.